Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by CARLOS E BUESO-RAMOS and JORGE E CORTES.
CARLOS E BUESO-RAMOS
Connection Strength
1.975
JORGE E CORTES
  1. Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia. Clin Lymphoma Myeloma Leuk. 2016 08; 16 Suppl:S86-92.
    View in: PubMed
    Score: 0.141
  2. CD105 (endoglin) is highly overexpressed in a subset of cases of acute myeloid leukemias. Am J Clin Pathol. 2013 Sep; 140(3):370-8.
    View in: PubMed
    Score: 0.115
  3. Digital image analysis as a tool to assess the effects of imatinib on trabecular bone in patients with chronic myelogenous leukemia. Hum Pathol. 2012 Dec; 43(12):2354-9.
    View in: PubMed
    Score: 0.107
  4. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. Cancer. 2005 Aug 15; 104(4):777-80.
    View in: PubMed
    Score: 0.066
  5. The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. Leuk Lymphoma. 2005 Jul; 46(7):993-7.
    View in: PubMed
    Score: 0.065
  6. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. Cancer. 2004 Jul 15; 101(2):332-6.
    View in: PubMed
    Score: 0.061
  7. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 09 15; 140(11):1200-1228.
    View in: PubMed
    Score: 0.054
  8. BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. Cancer. 2021 04 15; 127(8):1246-1259.
    View in: PubMed
    Score: 0.047
  9. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020 06; 95(6):612-622.
    View in: PubMed
    Score: 0.045
  10. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019 05 01; 125(9):1470-1481.
    View in: PubMed
    Score: 0.041
  11. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019 03; 9(3):370-383.
    View in: PubMed
    Score: 0.041
  12. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674.
    View in: PubMed
    Score: 0.041
  13. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun. 2018 07 10; 9(1):2670.
    View in: PubMed
    Score: 0.040
  14. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma. 2019 01; 60(1):37-48.
    View in: PubMed
    Score: 0.040
  15. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol. 2018 06 20; 36(18):1788-1797.
    View in: PubMed
    Score: 0.040
  16. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer. 2018 06 15; 124(12):2534-2540.
    View in: PubMed
    Score: 0.040
  17. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018 02; 93(2):277-285.
    View in: PubMed
    Score: 0.039
  18. Histomorphological responses after therapy with pegylated interferon a-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp Hematol Oncol. 2017; 6:30.
    View in: PubMed
    Score: 0.038
  19. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2016 Dec 15; 122(24):3812-3820.
    View in: PubMed
    Score: 0.035
  20. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016 06 02; 127(22):2742-50.
    View in: PubMed
    Score: 0.034
  21. Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. Am J Hematol. 2015 Sep; 90(9):769-73.
    View in: PubMed
    Score: 0.033
  22. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. J Hematol Oncol. 2015 Apr 08; 8:32.
    View in: PubMed
    Score: 0.032
  23. Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens. Clin Cancer Res. 2015 Jul 01; 21(13):3041-51.
    View in: PubMed
    Score: 0.032
  24. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol. 2015 Jan; 2(1):e12-20.
    View in: PubMed
    Score: 0.031
  25. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. J Hematol Oncol. 2014 Oct 04; 7:74.
    View in: PubMed
    Score: 0.031
  26. Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentation. Clin Lymphoma Myeloma Leuk. 2015 Jan; 15(1):47-51.
    View in: PubMed
    Score: 0.030
  27. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014 Jun; 28(6):1280-8.
    View in: PubMed
    Score: 0.029
  28. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood. 2013 Oct 17; 122(16):2807-11; quiz 2920.
    View in: PubMed
    Score: 0.029
  29. Value of oligonucleotide-based array comparative genomic hybridization for diagnosis of acute promyelocytic leukemia in a patient negative for t(15;17)(q24.1;q21.2)/promyelocytic leukemia-retinoic acid receptor, alpha by conventional cytogenetics and fluorescence in situ hybridization. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):507-10.
    View in: PubMed
    Score: 0.028
  30. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. 2013 Oct; 27(10):2081-3.
    View in: PubMed
    Score: 0.028
  31. Double-hit of FLT3 gene in a fatal case of acute myemonocytic leukaemia. J Clin Pathol. 2013 Sep; 66(9):826-9.
    View in: PubMed
    Score: 0.028
  32. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol. 2013 May; 88(5):365-9.
    View in: PubMed
    Score: 0.028
  33. Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. Leuk Lymphoma. 2013 Nov; 54(11):2537-9.
    View in: PubMed
    Score: 0.028
  34. Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase. J Clin Oncol. 2011 Jun 10; 29(17):e514-6.
    View in: PubMed
    Score: 0.024
  35. Targeting neuropilin-1 in human leukemia and lymphoma. Blood. 2011 Jan 20; 117(3):920-7.
    View in: PubMed
    Score: 0.024
  36. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010 Aug 20; 28(24):3880-9.
    View in: PubMed
    Score: 0.023
  37. Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients. Cancer. 2010 Jan 15; 116(2):369-76.
    View in: PubMed
    Score: 0.022
  38. Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia. 2009 Dec; 23(12):2275-80.
    View in: PubMed
    Score: 0.022
  39. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009 Oct 01; 27(28):4760-6.
    View in: PubMed
    Score: 0.022
  40. Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001. Int J Hematol. 2009 Jul; 90(1):58-63.
    View in: PubMed
    Score: 0.021
  41. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res. 2009 Jan 01; 15(1):368-73.
    View in: PubMed
    Score: 0.021
  42. BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias. Blood. 2008 Dec 15; 112(13):5190-2.
    View in: PubMed
    Score: 0.020
  43. Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies. Cancer. 2008 Jul 15; 113(2):360-6.
    View in: PubMed
    Score: 0.020
  44. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood. 2008 Sep 01; 112(5):1628-37.
    View in: PubMed
    Score: 0.020
  45. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008 Feb 01; 111(3):1060-6.
    View in: PubMed
    Score: 0.019
  46. Normal hematopoietic function and multiple bone marrow clonal abnormalities in a patient with acute myeloid leukemia after two mismatched stem-cell transplants with graft failure and autologous reconstitution. Am J Hematol. 2007 Aug; 82(8):744-7.
    View in: PubMed
    Score: 0.019
  47. Biphenotypic acute leukaemia: a case series. Br J Haematol. 2007 Jul; 138(2):213-6.
    View in: PubMed
    Score: 0.019
  48. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 2007 Mar 15; 109(6):1133-7.
    View in: PubMed
    Score: 0.018
  49. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007 Jan 01; 109(1):52-7.
    View in: PubMed
    Score: 0.018
  50. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006 Nov 15; 108(10):3271-9.
    View in: PubMed
    Score: 0.018
  51. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006 Apr 01; 106(7):1569-80.
    View in: PubMed
    Score: 0.017
  52. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood. 2006 Feb 01; 107(3):880-4.
    View in: PubMed
    Score: 0.016
  53. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer. 2005 Aug 01; 104(3):547-54.
    View in: PubMed
    Score: 0.016
  54. Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. Ann Oncol. 2005 Jan; 16(1):139-45.
    View in: PubMed
    Score: 0.016
  55. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004 Dec 15; 101(12):2788-801.
    View in: PubMed
    Score: 0.016
  56. Rituximab in relapsed or refractory hairy cell leukemia. Blood. 2003 Dec 01; 102(12):3906-11.
    View in: PubMed
    Score: 0.014
  57. The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma. Cancer. 2002 May 15; 94(10):2738-44.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.